SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,075,763,011.6159 in circulation. The last known price of Algorand is 0.09537939 USD and is up 2.17 over the last 24 hours. It is currently trading on 586 active market(s) with $72,099,657.31 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

Algorands post-quantum upgrade and AI-agent payment activity feature in bullish arguments, but the main discussion is whether its low-price consolidation signals a recovery or another failed bounce. Bulls cite accumulation and a possible altcoin-season rebound, while bears point to ALGOs steep long-term decline and ongoing selling pressure.

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00385003 USD and is up 3.25 over the last 24 hours. It is currently trading on 374 active market(s) with $20,884,591.23 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

JASMY is drawing attention amid weak, volatile trading, with traders split between buying dips and criticizing its prolonged underperformance. Bulls point to the AppBank AI/data-services collaboration and JasmyChain utility as potential adoption drivers, while skeptics say real usage and price impact have yet to materialize; some also blame broader crypto-market weakness.

Akamai Technologies, Inc. is the cybersecurity and cloud computing company that powers and protects business online. The market security solutions, superior threat intelligence, and global operations team provide defense in depth to safeguard enterprise data and applications everywhere. The firm full-stack cloud computing solutions deliver performance and affordability on the world’s most distributed platform. The global enterprises trust Akamai to provide the industry reliability, scale, and expertise they need to grow their business with confidence. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

A large, multiyear Anthropic cloud-infrastructure agreement has put Akamais AI-cloud pivot in focus, but the shares have sold off sharply after an initial rally. Traders are divided over whether the deal will drive significant growth or whether upfront capital spending, delayed revenue and reliance on one major customer outweigh the opportunity.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000495 USD and is up 9.16 over the last 24 hours. It is currently trading on 729 active market(s) with $1,489,033,091.54 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPEs volatile trading around a key price level is driving discussion, with bullish traders pointing to rebounds and potential breakouts while skeptics warn that gains keep fading and the token often moves with broader crypto weakness. No clear company- or market-specific catalyst is established; the conversation is mainly about price action and whether dips are being bought or sold.

Sky (SKY) is a cryptocurrency and operates on the Ethereum platform. Sky has a current supply of 23,452,431,915.60596656 with 23,422,827,962.33348843 in circulation. The last known price of Sky is 0.06706993 USD and is up 0.91 over the last 24 hours. It is currently trading on 257 active market(s) with $49,629,100.47 traded over the last 24 hours. More information can be found at https://sky.money/.

Skycoin

Traders are focused on reports of Galaxy Digital adding Skys yield-bearing token to its treasury and accepting it as collateral, with the broader institutional tie-up seen as a boost to the Sky ecosystem. Bulls point to rising volume and a possible breakout, while others caution that the recent rally could pull back; short-squeeze claims remain speculation.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl is drawing attention after Q3 results beat expectations, with traders highlighting AUM growth, fee earnings and managements upbeat outlook on dividend coverage and undeployed capital. The positive reaction is tempered by continuing concerns about fund redemptions and private-credit exposure, including data-center financing risks.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention amid a sharp selloff and concerns that share issuance through its expanded equity facility is diluting shareholders as the company raises capital to accumulate HYPE tokens. Bulls point to Hyperliquids growth and PURRs HYPE-treasury exposure, while bears argue dilution and the stocks failure to track HYPE are weighing on shares.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention as traders react to volatile crude prices amid U.S.-Iran tensions and fears of disruption to Middle Eastern oil flows. The community is split between expecting further gains if supply risks persist and anticipating a pullback if a peace deal materializes or oversupply concerns take hold.

Jersey Mike's Subs, Inc. engages in franchising fast casual, submarine-style sandwich restaurants specializing in authentic, hand-crafted, and craveable subs. The company was founded by Peter Cancro in 1956 and is headquartered in Tinton Falls, NJ.

Jersey Mike`s Subs Inc. - Ordinary Shares - Class A

Jersey Mikes quarterly results and updated growth outlook are driving attention, with traders also highlighting a share buyback and one-time dividend. Reactions are divided: some view the results and shareholder returns positively, while others remain concerned about the stocks post-IPO decline, valuation, debt, and private-equity ownership.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms quarterly results and outlook are driving attention, with traders focusing on stronger enterprise growth, AI-product adoption and a higher full-year forecast; bullish reactions contrast with concerns about modest overall growth and competitive pressure. The Anthropic stake and a potential IPO are also cited as a speculative source of value, though traders disagree on how much it may benefit Zoom.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

A $305 Billion Cancer Treatment Opportunity Is Putting Immuno-Oncology in the Spotlight   New York, NY – October 26, 2026 – Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are developing treatments that help the […]
The post Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market appeared first on Financial News Media.

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinical trials for multiple myeloma.read more...

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.read more...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic PR Newswire SAN FRANCISCO, May 18, 2026 Issued on behalf of GT Biopharma, Inc.SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group...

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally

Equity

Neutral Sentiment

Shares of GT Biopharma had their best trading day in more than nine months after the company shared encouraging progress from its ongoing Phase 1 trial of GTB-3650, an experimental treatment for patients with relapsed or refractory CD33-positive blood cancers.The stock jumped 43.7% to $1.08 at Wednesday’s close, before slipping 10.5% in after-hours trading.The clinical-stage biotech company said enrollment in the study’s dose-escalation groups is progressing smoothly and remains “well on track.” Both patients in Cohort 3 have now begun treatment, with no signs of dose-limiting toxicities or tolerability issues so far.&nbsp;The company added that the first patient in Cohort 3 has shown “promising evidence of immune activation,” matching the levels of activity seen in patients from the two earlier, lower-dose groups.GT Biopharma's trial will evaluate the safety, pharmacokinetics/pharmacodynamics of GTB-3650, and evidence of immune activation. GTB-3650 will use the company's TriKE platform to recruit natural killer (NK) cells to fight cancer.The Phase 1 study can enroll up to 14 patients, with two people in each of seven planned dosing groups. The lowest dose starts at 1.25 micrograms per kilogram per day and could go up to 100 micrograms per kilogram per day in the highest group. Each patient will take the drug in two-week treatment cycles, with two weeks on therapy followed by two weeks off, for as long as four months if they continue to show signs of clinical benefit.If Cohort 3 is dosed without any problems, GT Biopharma anticipates dosing the first patient in Cohort 4 by the end of 2025. The dose level can be increased further if warranted. The company expects to provide an update on additional data by the end of 2025 and in the first quarter of 2026 as it moves to the higher dose levels in the trial that may yield more robust therapeutic effects.On Stocktwits, retail sentiment for GT Biopharma was ‘extremely bullish’ amid a 2,933% surge in 24-hour message volume.One user said that GT Biopharma shares appeared to be gaining strong upward momentum and could move toward double-digit levels.&nbsp;<stembedurl>https://stocktwits.com/Illbeyourhuckleberree/message/631516421</stembedurl>Another user commented that the company’s cancer therapy showed significant promise, with the potential for substantial long-term returns.<stembedurl>https://stocktwits.com/Djdanny/message/631566315</stembedurl><a href="https://stocktwits.com/symbol/GTBP">GT Biopharma’s stock</a> has declined 65% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

GT Biopharma’s stock (GTBP) has declined 65% so far in 2025. (Photo credit: Getty Images)

The biotech firm reported smooth progress in its Phase 1 trial of GTB-3650, with no safety issues and early signs of immune activation in the latest dosing group. 

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$GTBP Looks like a very competitive field vs. IBRX...almost as though one spawned tother? js...glta

Fractions1

$GTBP – Your Own Immune System as the Drug 
 
GT Biopharma's TriKE platform turns a patient's own natural killer cells into cancer hunters — and unlike CAR-T, there's no patient-specific manufacturing. It's off-the-shelf. 
 
Two candidates already in Phase 1, a new multiple myeloma indication just cleared by the FDA, and readouts expected in Q4. 
 
One platform, multiple shots on goal.  
 
Holding DEMAND/ SUPPORT atm.

The Swing Scout

$GTBP ha, companies are announcing offerings on Friday afternoons, theirs is the 5th one in the last hour

Feed

News

Sentiment

Earnings

Fundamentals

Info

GTBP GT Biopharma Inc

Fundamentals

Latest GTBP News